Phathom Pharmaceuticals, Inc. Stock Price, News & Analysis

Phathom Pharmaceuticals (Nasdaq: PHAT) reported Q3 2025 results on October 30, 2025: net revenue $49.5M (up 25% sequentially), ~221,000 VOQUEZNA prescriptions filled in Q3 and >790,000 total filled prescriptions to date. Cash operating metrics improved: cash and cash equivalents $135.2M and net cash usage ~$14M in Q3 (a 77% improvement vs Q2). Operating expenses declined sequentially with non-GAAP operating expense $49.3M in Q3 and guidance of $170–$175M full-year 2025 revenue. The company expects to achieve operating profitability in 2026 (excluding stock-based compensation) and initiated a Phase 2 EoE trial with topline results anticipated in 2027.

Phathom Pharmaceuticals (NASDAQ: PHAT) reported publication of Phase 3 pHalcon-NERD-301 data in the American Journal of Gastroenterology showing VOQUEZNA (vonoprazan) produced rapid and sustained relief of nocturnal GERD symptoms.

In 772 randomized patients, mean heartburn-free nights at Week 4 were 59.9% (10 mg) and 56.4% (20 mg) vs 43.3% for placebo (nominal p<0.0001); separation appeared after the first dose. Median heartburn-free nights remained >70% through the 20-week extension. VOQUEZNA improved N-GSSIQ scores for nocturnal severity and concern and was generally well tolerated with common AEs ≤5% in the extension.

Phathom Pharmaceuticals (Nasdaq: PHAT) will highlight VOQUEZNA® (vonoprazan) at the American College of Gastroenterology (ACG) 2025 Annual Scientific Meeting in Phoenix, Oct 24–29, 2025.

Phathom will staff exhibit booth #214, host a VOQUEZNA product theater on Oct 27, 3:45–4:30 pm MST featuring Dr. John Erik Pandolfino, and supported an IME Medscape program, “Decision Points in the Management of GERD,” on Oct 25, 6:00–7:15 pm MST. VOQUEZNA is described as an approved potassium-competitive acid blocker for healing and maintenance of erosive GERD and relief of heartburn in non-erosive GERD; the summary notes key safety warnings and monitoring recommendations in the prescribing information.

Phathom Pharmaceuticals (Nasdaq: PHAT) announced it will report third quarter 2025 financial results and provide a business update via live webcast on Thursday, October 30, 2025 at 8:00 AM EDT.

The live webcast and presentation materials will be available on the company's Events & Presentations page and a recording will be posted for 90 days after the call. Phathom develops gastrointestinal therapies and markets VOQUEZNA (vonoprazan) products in the U.S., including VOQUEZNA tablets for GERD and VOQUEZNA DUAL PAK/TRIPLE PAK for H. pylori treatment.

Media and investor contact details are provided for additional inquiries.

Phathom Pharmaceuticals (NASDAQ: PHAT) appointed Sanjeev Narula as Chief Financial and Business Officer on October 6, 2025. Mr. Narula is described as experienced in scaling commercial-stage biopharma companies with expertise in capital and investor strategies, mergers & acquisitions, and operations.

Management says the hire strengthens leadership as Phathom executes its growth strategy, targets profitability, and commercializes VOQUEZNA, which the company says is gaining traction.

Phathom Pharmaceuticals (NASDAQ: PHAT), a biopharmaceutical company specializing in gastrointestinal treatments, has announced its participation in two upcoming investor conferences in September 2025. The company will present at the Cantor Global Healthcare Conference on September 3 at 9:10 am EDT and the H.C. Wainwright Global Investment Conference on September 8 at 1:00 pm EDT.

Phathom's management team will conduct one-on-one meetings during both conferences. The company currently markets VOQUEZNA®, a first-in-class potassium-competitive acid blocker (PCAB) for various gastrointestinal conditions including Non-Erosive GERD and H. pylori infection treatment.

Phathom Pharmaceuticals (NASDAQ: PHAT) has issued a clarification regarding a Schedule 13D filing by Frazier Life Sciences. The company emphasized that the upcoming filing includes only administrative changes to the reporting approach and does not represent any reduction in Frazier's ownership position in Phathom.

While the updated filing may show different breakouts of holdings between funds and persons, and changes in warrant treatment may affect certain percentage calculations, these modifications are purely administrative in nature. The company confirms that no actual sale of shares has occurred.

Phathom Pharmaceuticals (NASDAQ:PHAT) reported strong Q2 2025 financial results, with net revenues of $39.5 million, up significantly from $7.3 million in Q2 2024. The company's VOQUEZNA® products reached over 580,000 filled prescriptions, showing 49% growth since the last earnings report. Commercial coverage remains robust with access to over 120 million lives.

The company provided full-year 2025 revenue guidance of $165-175 million and expects to achieve profitability in 2026. Q2 net loss was $75.8 million, improved from $91.4 million in Q2 2024. Cash position stands at $149.6 million as of June 30, 2025. The FDA has updated VOQUEZNA's exclusivity through May 2032, with generic entry unlikely before 2033.

Phathom Pharmaceuticals (NASDAQ: PHAT), a biopharmaceutical company specializing in gastrointestinal disease treatments, will host a webcast on August 7, 2025, at 8:00 am EDT to discuss Q2 2025 financial results and provide a business update.

The company markets VOQUEZNA® (vonoprazan) tablets in the US for heartburn relief and GERD treatment, along with VOQUEZNA® TRIPLE PAK® and VOQUEZNA® DUAL PAK® for H. pylori infection treatment. The webcast will be accessible through Phathom's investor relations website, with a recording available for 90 days following the event.